|
|
EQSNews: Imcyse SA
/ Key words: Study
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY0141 for the Treatment of Multiple Sclerosis
13.09.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Imcyse SA
/ Key words: Miscellaneous
Imcyse joins CLAIMS, a European Health Initiative Project to Make DataDriven Precision Medicine a Reality for Patients with Multiple Sclerosis
22.06.2023 / 10:30 CET/CEST
The issuer is solely responsible for the content of this announcement.... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Imcyse SA
/ Key words: Study
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY0098 for Type 1 Diabetes
01.03.2023 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY0098 for... Lire le communiqué |
|
| |
|
| |
|
|
DGAPNews: Imcyse SA
/ Key words: Study
13.04.2022 / 13:00
The issuer is solely responsible for the content of this announcement.
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY0141 for Multiple Sclerosis
... Lire le communiqué |
|
| |
|
| |
|
|
DGAPNews: Imcyse SA
/ Key words: Conference
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
14.03.2022 / 12:00
The issuer is solely responsible for the content of this announcement.
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
Liège, Belgium... Lire le communiqué |
|
| |
|
| |
|
|
DGAPNews: Imcyse SA
/ Key words: Miscellaneous
Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
13.01.2022 / 13:00
The issuer is solely responsible for the content of this announcement.
Imcyse Reports Positive Immune Response from Interim Analysis of P... Lire le communiqué |
|
| |
|
| |
|
|
DGAPNews: Imcyse SA
/ Key words: Personnel
Imcyse Appoints Gene Mack, MBA as Chief Financial Officer
03.11.2021 / 13:00
The issuer is solely responsible for the content of this announcement.
Imcyse Appoints Gene Mack, MBA as Chief Financial Officer
Liège, Belgium, November 3, 2021 Imcyse... Lire le communiqué |
|
| |
|
| |
